YouTube Outage Disrupts Thousands Worldwide as Recommendation System Fails 
Freedom Finance and Binance Join Forces in Digital Assets 
Qualcomm to Invest $150 Million in India AI Startups, Strengthening Presence in Growing Market 
AstroTurf Expands Footprint at Colorado as Buffaloes Complete Second Installation in 12 Months 
Hedge Funds Cut Nvidia, Amazon and Microsoft Stakes as AI Valuation Concerns Rise 
Texas Attorney General Ken Paxton Sues Sanofi Over Alleged Healthcare Bribery Scheme 
Vietnam Airlines, Vietjet, and Sun PhuQuoc Airways Sign Major Boeing Aircraft Deals Amid U.S.–Vietnam Trade Talks 
Nvidia Nears $30 Billion Investment in OpenAI, Replacing Previous $100 Billion AI Partnership 
Waymo Clarifies Role of Remote Workers Amid U.S. Robotaxi Safety Scrutiny 
Reese’s Peanut Butter Cup Recipe Debate: Hershey Responds as Cocoa Prices Shift 
Microsoft Plans $50 Billion AI Investment to Accelerate Growth in the Global South 
Citigroup Private Bank Appoints Chad Reddy as West Market Executive in North America 
OpenAI Nears $100 Billion Funding Round at $850 Billion Valuation: Bloomberg Report 
Amazon Surpasses Walmart in Annual Revenue, Signaling a New Era in Retail Competition 
LAS VEGAS, May 08, 2018 -- CV Sciences, Inc., (OTCQB:CVSI) a preeminent manufacturer and distributor of hemp-derived phytocannabinoids including CBD oil, today announced that it is scheduled to host a conference call to discuss its first quarter 2018 financial results on Tuesday, May 15, 2018 at 1:15pm PT / 4:15pm ET.
CV Sciences’ CFO Joseph Dowling will lead the call to provide an operational and financial summary of the first quarter ended March 31, 2018. Interested parties may access the live webcast by visiting: https://78449.themediaframe.com/dataconf/productusers/cvsciences/mediaframe/24633/indexl.html
In order to ensure adequate time for any software downloads that may be necessary to listen to the webcast, attendees are encouraged to connect to the website 10-15 minutes prior to the live event.
Participants may also access the listen-only audio call by dialing 1-877-407-8293 (United States) or 1-201-689-8349 (International). If you are unable to participate in the call at this time, a replay will be available for 14 days starting on May 15, 2018, at approximately 7:30 p.m. PT/10:30 p.m. ET. To access the replay, please dial 1-877-660-6853 in the U.S. and 1-201-612-7415 for international callers. The conference ID# is 13679917.
About CV Sciences, Inc.
CV Sciences, Inc (OTCQB:CVSI), located in Las Vegas, Nevada, focuses on drug development activities on products containing cannabidiol (CBD) as the active pharmaceutical ingredient, and also is engaged in the sale of CBD, and the development, marketing and sale of end consumer products containing CBD, which is refined into its own PlusCBD Oil™ brand. Additional information is available from OTCMarkets.com or by visiting PlusCBDoil.com.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.
CONTACT INFORMATION:
Robert Haag
Managing Director
IRTH Communications
[email protected]
866-976-4784
